Trial Profile

A Phase 1b Study of Safety and Immune Response to PVX-410 Vaccine Alone and in Combination with Durvalumab in Human Leukocyte Antigen (HLA)-A2+ Subjects Following Standard Treatment of Stage II or III Triple Negative Breast Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 13 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PVX 410 (Primary) ; Durvalumab; Poly ICLC
Indications Advanced breast cancer; Early breast cancer; Triple negative breast cancer
Focus Adverse reactions

01 Oct 2025 Planned End Date changed from 1 Sep 2026 to 1 Sep 2027.
01 Oct 2025 Planned primary completion date changed from 1 Jun 2025 to 1 Dec 2026.
23 Sep 2024 Planned End Date changed from 1 Sep 2025 to 1 Sep 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com